“Psilocybin will be legalized in the United States in two to three years”
Psychologist, psychonaut and teacher, Iker Puente will also participate in Fuertedélica, the Psychedelic Conference of Fuerteventura. Around 500 therapists and scientists work in Spain in the field of psychedelics applied to mental health, most of them underground, according to Iker Puente‘s estimates. Iker knows this well, as many of them have trained at the Integrative…
Tantra and MDMA as vehicles to shake off centuries of Western puritanism
Raúl del Pino, author of the book ‘MDMA, Sex and Tantra’, will participate in Fuertedélica as a member of the round table ‘MDMA, from party to couch’, along with Fernando Caudevilla and José Carlos Bouso. Below, and to warm up, an extract from the first chapter of the mentioned book: “Under the effects of ecstasy,…
“Psychedelics will eventually be incorporated into the healthcare sector… but the system’s pace is glacial”
We analyze the present & future of psychedelic medicine with psychiatrist Juan París Juan París, psychiatrist and psychedelic researcher, attends Fuertedélica as a representative of the Spanish Society of Psychedelic Medicine (SEMPSI), one of the most active forums in the effort to integrate psychedelic substances into the Spanish healthcare system. París is one of the…
Hotel, Flights, Transfers: Everything You Need to Know to Happily Arrive at Fuertedélica
On the morning of November 22, the third edition of Fuertedélica begins in Corralejo. It will start with a free round table that will bring together some of the brightest young Spanish researchers in the field of psychedelics. Many of you are asking what you need to do to participate in the conference, stay in…
“Ibogaine allows you to break free from the chemical iron chain of methadone”
Anthropologist Antoniu Llort will share at Fuertedélica the results of the clinical trial with ibogaine for methadone detoxification, whose Phase II has just concluded at Sant Joan Hospital in Reus. In Llort’s words, it is “an exciting study that could mark a before and after in the treatment of methadone dependence.” Don’t miss Antoniu’s presentation…
“The refusal to authorize MDMA as a medication has done a huge favor to ‘underground’ therapy”
2024 was expected to be the year of the consolidation of the “psychedelic renaissance.” However, the FDA, the drug regulatory agency in the US, has rejected the approval of MDMA as a treatment for post-traumatic stress. José Carlos Bouso, scientific director of ICEERS and speaker at Fuertedélica, analyzes in this interview the causes behind this…
The Path to Pain Relief: Examining Ayahuasca’s Possible Benefits for Fibromyalgia Sufferers
Rafael Guimarães dos Santos is a world-renowned expert in scientific research on ayahuasca. A disciple of Jordi Riba at Sant Pau Hospital, Dos Santos leads several cutting-edge investigations with ayahuasca, ibogaine, and ketamine within the Department of Neuroscience and Behavioral Sciences at the University of São Paulo. In this interview, the Brazilian researcher gives us…
“There is a danger looming over ayahuasca: spiritual appropriation”
What’s the biggest danger looming over ayahuasca? In 2018, in the wake of the tragic murder of the maestra Olivia Arévalo at the hands of an ayahuasca tourist, the healers of the Shipibo-Konibo ethnic group founded ASOMASHK, an association that brings together more than 150 traditional healers who work in all areas of traditional medicine…
“Ketamine provides a detached and new perspective on oneself”
Estefanía Moreno will be part of the round table “Climbing Out of the Hole: Ketamine and Mental Health,” next Saturday, November 23rd, at Fuertedélica. Moreno is a doctor with training in Psychoneuroimmunology and Transpersonal Psychology, and she conducts ketamine-assisted psychotherapy at Clínica Synaptica, a pioneering center in Catalonia for psychedelic therapy. More than 240 patients…
From the Dance Floor to the Therapy Couch: A Brief History of MDMA
MDMA was first synthesized by Anton Köllisch at the pharmaceutical company Merck in Germany. The young German chemist developed 3,4-methylenedioxymethamphetamine in his quest for an alternative chemical method to synthesize hydrastinine. The molecule was patented on December 24, 1912, but was never tested on humans. With the outbreak of World War I, Köllisch was recruited…
